Total Payments
$256,211
2024 Payments
$6,281
Companies
19
Transactions
159
Medicare Patients
792
Medicare Billing
$83,824
Payment Breakdown by Category
Consulting$196,598 (76.7%)
Other$30,913 (12.1%)
Travel$22,278 (8.7%)
Food & Beverage$6,075 (2.4%)
Research$344.22 (0.1%)
Education$3.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $196,598 | 29 | 76.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,913 | 12 | 10.9% |
| Travel and Lodging | $22,278 | 35 | 8.7% |
| Food and Beverage | $6,075 | 78 | 2.4% |
| Honoraria | $3,000 | 3 | 1.2% |
| Unspecified | $344.22 | 1 | 0.1% |
| Education | $3.13 | 1 | 0.0% |
Payments by Type
General
$255,867
158 transactions
Research
$344.22
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $155,048 | 35 | $0 (2022) |
| Janssen Research & Development, LLC | $34,991 | 5 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $27,997 | 45 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $15,545 | 6 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $12,408 | 25 | $0 (2023) |
| AltaThera Pharmaceuticals LLC | $5,327 | 7 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $2,680 | 3 | $0 (2018) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $530.48 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $465.47 | 9 | $0 (2019) |
| Amgen Inc. | $405.77 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,281 | 5 | Janssen Research & Development, LLC ($4,178) |
| 2023 | $6,191 | 3 | Janssen Research & Development, LLC ($6,013) |
| 2022 | $25,062 | 9 | Janssen Research & Development, LLC ($24,801) |
| 2021 | $2,500 | 1 | BOSTON SCIENTIFIC CORPORATION ($2,500) |
| 2020 | $18,586 | 10 | SANOFI-AVENTIS U.S. LLC ($15,511) |
| 2019 | $23,099 | 47 | Boston Scientific Corporation ($13,923) |
| 2018 | $21,486 | 31 | PFIZER INC. ($12,340) |
| 2017 | $153,006 | 53 | PFIZER INC. ($142,584) |
All Payment Transactions
159 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AltaThera Pharmaceuticals LLC | Sotalol Hydrochloride (Drug) | Food and Beverage | Cash or cash equivalent | $2.37 | General |
| Category: Cardiovascular | ||||||
| 11/15/2024 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $27.66 | General |
| 05/24/2024 | AltaThera Pharmaceuticals LLC | Sotalol Hydrochloride (Drug) | Food and Beverage | Stock, stock option, or any other ownership interest | $1,875.00 | General |
| Category: Cardiovascular | ||||||
| 04/22/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,150.22 | General |
| 04/02/2024 | AltaThera Pharmaceuticals LLC | Sotalol Hydrochloride (Drug) | Food and Beverage | Cash or cash equivalent | $225.94 | General |
| Category: Cardiovascular | ||||||
| 10/31/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $135.00 | General |
| 06/21/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $43.65 | General |
| 02/27/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $6,012.50 | General |
| 11/21/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $15,050.77 | General |
| 10/14/2022 | PFIZER INC. | VYNDAQEL (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/13/2022 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $23.01 | General |
| 09/05/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $9,750.00 | General |
| 08/23/2022 | PFIZER INC. | VYNDAQEL (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/20/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Cardiology | ||||||
| 04/29/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/08/2022 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $32.39 | General |
| 02/22/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.80 | General |
| Category: Cardiovascular | ||||||
| 09/21/2021 | BOSTON SCIENTIFIC CORPORATION | WATCHMAN (Device) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: STRUCTURAL HEART | ||||||
| 12/04/2020 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Consulting Fee | Cash or cash equivalent | $5,148.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2020 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,608.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/03/2020 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,605.00 | General |
| 08/12/2020 | Boston Scientific Corporation | WATCHMAN (Device) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: STRUCTURAL HEART | ||||||
| 06/24/2020 | Boston Scientific Corporation | WATCHMAN (Device) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: STRUCTURAL HEART | ||||||
| 05/06/2020 | AltaThera Pharmaceuticals LLC | Sotalol Hydrochloride (Drug) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Cardiovascular | ||||||
| 04/28/2020 | SANOFI-AVENTIS U.S. LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Active Warfarin Controlled Randomized Double Blind Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism | E.R. Squibb & Sons, L.L.C. | $344.22 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 41 | 157 | $25,390 | $13,963 |
| 2022 | 3 | 329 | 550 | $41,250 | $18,848 |
| 2021 | 3 | 156 | 389 | $49,410 | $28,190 |
| 2020 | 5 | 266 | 529 | $49,475 | $22,822 |
Total Patients
792
Total Services
1,625
Medicare Billing
$83,824
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 94 | $23,500 | $13,302 | 56.6% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 20 | 63 | $1,890 | $661.54 | 35.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 104 | $26,000 | $15,594 | 60.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 284 | 374 | $13,090 | $2,479 | 18.9% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2022 | 20 | 72 | $2,160 | $774.90 | 35.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 176 | $42,350 | $26,384 | 62.3% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 107 | 134 | $4,690 | $938.00 | 20.0% |
| 93040 | Tracing of electrical activity of heart using 1-3 leads with interpretation and report | Office | 2021 | 22 | 79 | $2,370 | $868.21 | 36.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 25 | 127 | $25,400 | $15,134 | 59.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 46 | $6,900 | $4,086 | 59.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 195 | 290 | $10,075 | $2,075 | 20.6% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 11 | 16 | $5,600 | $999.58 | 17.8% |
| 93040 | Tracing of electrical activity of heart using 1-3 leads with interpretation and report | Office | 2020 | 21 | 50 | $1,500 | $528.14 | 35.2% |
About Dr. Michael Ezekowitz, MD
Dr. Michael Ezekowitz, MD is a Cardiovascular Disease healthcare provider based in Broomall, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366413296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ezekowitz, MD has received a total of $256,211 in payments from pharmaceutical and medical device companies, with $6,281 received in 2024. These payments were reported across 159 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($196,598).
As a Medicare-enrolled provider, Ezekowitz has provided services to 792 Medicare beneficiaries, totaling 1,625 services with total Medicare billing of $83,824. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Broomall, PA
- Active Since 01/30/2006
- Last Updated 01/15/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1366413296
Products in Payments
- ELIQUIS (Drug) $164,978
- WATCHMAN (Device) $20,990
- MULTAQ (Drug) $6,790
- Sotalol Hydrochloride (Drug) $4,327
- GENERAL THERAPIES (Device) $3,507
- XARELTO (Drug) $2,799
- WATCHMAN DEVICE (Device) $2,645
- THERAPIES (Device) $854.44
- PRADAXA (Drug) $559.31
- Repatha (Biological) $389.99
- MAA868 (Drug) $305.05
- PRALUENT ALIROCUMAB INJECTION (Biological) $236.76
- CHANTIX (Drug) $196.87
- ENTRESTO (Drug) $160.42
- Circulatory Support (Device) $146.75
- VYNDAQEL (Drug) $37.61
- BRILINTA (Drug) $24.01
- TEGSEDI (Drug) $23.22
- AUVI-Q (Drug) $18.43
- Corlanor (Drug) $15.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Broomall
Dr. Mark Edelstein, M.d, M.D
Cardiovascular Disease — Payments: $8,523
Cardiovascular Disease $8,523
Michael Valentino, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $8,271
Cardiovascular Disease $8,271
Dr. Michael Tobin, M.d, M.D
Cardiovascular Disease — Payments: $7,558
Cardiovascular Disease $7,558
Dr. Richard Lichtenberg, M.d, M.D
Cardiovascular Disease — Payments: $5,465
Cardiovascular Disease $5,465
Dr. Julian Gladstone, M.d, M.D
Cardiovascular Disease — Payments: $4,038
Cardiovascular Disease $4,038
Dr. Mark Lisberger, M.d, M.D
Cardiovascular Disease — Payments: $3,319
Cardiovascular Disease $3,319